Platinum, Palladium...
Health Care: Drugs
Arqule Inc. (ARQL: NASDAQ)
$2.40 -0.03 | -1.23%
06/19/13 - 11:50 AM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 14.33M | 11.10M | 20.46M | 36.55M |
| Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 79.62M | 72.19M | 81.81M | 157.15M |
| Property, Plant & Equipment, Gross | 22.26M | 22.14M | 21.55M | 21.19M |
| Accumulated Depreciation & Depletion | 20.27M | 19.20M | 18.03M | 16.60M |
| Property, Plant & Equipment, Net | 1.99M | 2.94M | 3.52M | 4.58M |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 52.59M | 41.92M | 3.54M | 10.14M |
| Total Non-Current Assets | 54.58M | 44.86M | 7.05M | 14.73M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 134.19M | 117.05M | 88.87M | 171.88M |
| Accounts Payable | 560.00K | 226.00K | 1.26M | 8.37M |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 552.00K | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 26.65M | 48.89M | 46.91M | 83.58M |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 784.00K | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 25.73M | 38.43M | 56.52M | 76.76M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 26.52M | 38.43M | 56.52M | 76.76M |
| Total Liabilities | 53.16M | 87.32M | 103.43M | 160.34M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 81.03M | 29.73M | -14.56M | 11.54M |
| Common Par | 624.00K | 538.00K | 450.00K | 448.00K |
| Additional Paid In Capital | 500.66M | 438.68M | 383.71M | 379.62M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -420.35M | -409.48M | -398.72M | -368.59M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 102.00K | -6.00K | -7.00K | 55.00K |
| Total Capitalization | 81.03M | 29.73M | -14.56M | 11.54M |
| Total Equity | 81.03M | 29.73M | -14.56M | 11.54M |
| Total Liabilities & Stock Equity | 134.19M | 117.05M | 88.87M | 171.88M |
| Total Common Shares Outstanding | 62.40M | 53.83M | 44.97M | 44.77M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 59.82M | 52.78M | 44.53M | 44.17M |
| Diluted Weighted Shares Outstanding | 59.82M | 52.78M | 44.53M | 44.17M |
| Number of Employees | 97 | 103 | 115 | 111 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with ARQL
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- UserD-ZYRE
- User2012 picks 10/28/20121
- ContributorBreakout Stocks Of The Week...
- Contributor22 Biopharma Stocks With Br...
Latest ARQL Headlines from TheStreet
- 10 ASCO '13 Abstracts You Can Read Right Now 05.15.13 | 06:05 pm
- 5 Under-$10 Stocks Setting Up to Trade Higher 11.30.12 | 12:11 pm
- 5 Stocks Poised for Breakouts 10.26.12 | 01:10 pm
- Stocks Drop on Eurozone, Earnings Anxieties 10.02.12 | 02:10 pm
- Arqule Shutters Lung Cancer Study Early Due to Futility 10.02.12 | 07:10 am
- Arqule Shares Slide on Lung Cancer Drug Safety Concern 08.29.12 | 10:08 am
- ASCO 2012 Live Blog -- Saturday 06.02.12 | 07:06 am
- 22 Biopharma Stocks With Breakout Potential in 2012 05.22.12 | 08:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update) 05.17.12 | 06:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus 05.16.12 | 06:05 pm
Press Releases for ARQL
- ArQule Reports Fiscal 2012 Year End And Fourth Quarter Results - Business Wire 03.14.13 | 07:03 am
- ArQule To Report Fiscal 2012 Financial Results On March 14, 2013 - Business Wire 03.07.13 | 08:03 am
- ArQule, Inc. To Present At Cowen And Company 33rd Annual Health Care Conference - Business Wire 02.27.13 | 08:02 am
- ArQule, Inc. To Present At RBC Capital Markets Global Healthcare Conference - Business Wire 02.19.13 | 08:02 am
- ArQule, Inc. To Present At Leerink Swann Global Healthcare Conference - Business Wire 02.07.13 | 08:02 am
- Daiichi Sankyo And ArQule Enroll First Hepatocellular Carcinoma Patient Into Global Phase 3 Trial For Tivantinib - Business Wire 01.31.13 | 08:01 am
- Daiichi Sankyo And ArQule Announce Top-Line Results Of Phase 2 Trial With Tivantinib In Colorectal Cancer - Business Wire 01.11.13 | 07:01 am
- ArQule Enrolls First Patient In Phase 1 Trial With ARQ 087, An FGFR Inhibitor - Business Wire 12.13.12 | 08:12 am
- ArQule, Inc. To Present At Oppenheimer Healthcare Conference - Business Wire 12.05.12 | 04:12 pm
- ArQule, Inc. To Present At Lazard Healthcare Conference - Business Wire 11.07.12 | 08:11 am
Partner Headlines for ARQL
- ArQule Earnings: Everything You Must Know Now - Wall St. Cheat Sheet 05.08.13 | 10:05 am
- Zacks #1 Rank Additions for Wednesday - Tale of the Tape - Zacks 10.03.12 | 09:10 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 08.07.12 | 09:08 am
- Teradyne DROPS 16% in Recent Weeks and 4 Fresh Analyst Insights - Wall St. Cheat Sheet 07.06.12 | 01:07 pm
- Five Stocks With Heavy Insider Trading - Benzinga 06.11.12 | 01:06 pm
- Stock Insights: Dendreon, Medtronic, FedEx, ArQule, Rentrak June 4th - Wall St. Cheat Sheet 06.04.12 | 10:06 am
- ArQule Announces Positive Phase 2 Study Results for Tivantinib in Previously Treated Hepatocellular Carcinoma - Benzinga 06.02.12 | 06:06 pm
- Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 3 - Seeking Alpha 05.25.12 | 08:05 pm
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 05.01.12 | 09:05 am
- Zacks #1 Rank Additions for Monday - Tale of the Tape - Zacks 04.02.12 | 09:04 am
